| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 15, 2024 | Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial | |
| May 7, 2024 | Topas Therapeutics Appoints Hugo Fry as CEO | |
| Feb 27, 2024 | Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP | |
| Jan 30, 2024 | Allecra Licensor Advanz receives positive CHMP opinion for EXBLIFEP | |
| Jun 27, 2023 | Allecra Therapeutics Submits New Drug Application to the U.S. FDA | |
| Oct 5, 2022 | Allecra Publishes Final Phase 3 ALLIUM Data in JAMA | |
| Feb 15, 2022 | Topas Therapeutics Appoints Cristina de Min, M.D. as Chief Medical Officer | |
| Jan 13, 2022 | Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe | |
| Jan 12, 2022 | BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies | |
| Jul 27, 2021 | Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) | |
| Jul 27, 2021 | Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round | |
| Oct 23, 2020 | Allecra Therapeutics Announces Late-breaker Presentation of Phase 3 ALLIUM Trial with Cefepime-Enmetazobactam in cUTIs at IDWeek 2020 | |
| Oct 23, 2020 | Allecra Therapeutics Announces Late-breaker Presentation of Phase 3 ALLIUM Trial | |
| Oct 19, 2020 | Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing | |
| Oct 19, 2020 | Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer | |
| Jul 2, 2020 | Immatics Announces Completion of Business Combinationand Listing on NASDAQ | |
| Jun 4, 2020 | Immatics Appoints Cedrik Britten as Chief Medical Officer | |
| Mar 17, 2020 | Immatics Announces Business Combination with Arya Sciences | |
| Feb 25, 2020 | Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 | |
| Feb 21, 2020 | Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies | |
| Dec 18, 2019 | Topas Therapeutics Announces First Patient Enrolled in Phase 1 Trial with TPM203 in Pemphigus Vulgaris | |
| Sep 24, 2019 | Amphivena Closes $62 Million Series C Financing | |
| Sep 12, 2019 | Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey | |
| Aug 28, 2019 | Immatics and Celgene Enter Strategic Collaboration to Develop Novel Adoptive Cell Therapies | |
| Jul 19, 2019 | Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients | |
| Jul 8, 2019 | Immatics Appoints Harpreet Singh as Chief Executive Officer | |
| Apr 9, 2019 | Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers | |
| Feb 26, 2019 | Immatics announces Clinical Trial Collaboration in Immunotherapy for Solid Cancers | |
| Jan 3, 2019 | US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies | |
| Dec 20, 2018 | Nature publication reports first-in-human trial for a personalized cancer immunotherapy | |
| Nov 27, 2018 | Arsanis and X4 Pharmaceuticals Agree to Merger | |
| Oct 25, 2018 | Opsona Therapeutics to present results on Tomaralimab study at the 60th Annual Meeting of the American Society of Hematology (ASH) | |
| Sep 13, 2018 | EMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) Transaction. | |
| Sep 11, 2018 | Crescendo Biologics Appoints Dr Pavel Pisa as Chief Medical Officer | |
| Aug 23, 2018 | Allecra Therapeutics Successfully Enters Next Development Phase | |
| Jul 12, 2018 | Immatics Enters into a Strategic Partnership with Genmab | |
| May 14, 2018 | Immatics Appoints Stephen Eck as Chief Medical Officer US | |
| Apr 30, 2018 | Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing | |
| Apr 24, 2018 | Topas Therapeutics and BI Sign Multi-Year Collaboration and Option Agreement | |
| Mar 26, 2018 | Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 | |
| Mar 12, 2018 | ViraTherapeutics starts 2nd development program with Boehringer Ingelheim | |
| Feb 15, 2018 | Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic | |
| Jan 25, 2018 | Topas Therapeutics serves as exclusive translational partner for CRC | |
| Dec 21, 2017 | Immatics Proprietary Target Selected for the Devel. of Cancer Immunotherapies | |
| Dec 19, 2017 | Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO | |
| Dec 19, 2017 | Immatics Appoints Thomas Ulmer as CFO | |
| Dec 8, 2017 | Apellis Pharmaceuticals Presents Update on Phase 1b PHAROAH Trial of APL-2 | |
| Dec 4, 2017 | Allecra Therapeutics Announces New Staged Financing Deal | |
| Nov 30, 2017 | Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017 | |
| Nov 20, 2017 | Arsanis Announces Closing of Initial Public Offering | |
| Nov 13, 2017 | Apellis Pharmaceuticals Announces Closing of its Initial Public Offering | |
| Nov 2, 2017 | Topas Therapeutics extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund | |
| Oct 26, 2017 | Topas Therapeutics Appoints Rupert Sandbrink as CDO and CMO | |
| Oct 4, 2017 | Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies | |
| Sep 28, 2017 | Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine® | |
| Sep 7, 2017 | Allecra Announces Initiation of a Phase 2 Clinical Trial | |
| Aug 22, 2017 | Immatics Initiates a Phase I trial using ACTolog | |
| Jun 16, 2017 | Crescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards | |
| May 8, 2017 | EMBL Ventures portfolio company Luxendo acquired by Bruker | |
| Apr 26, 2017 | Arsanis Completes $45.5 Million Series D Financing | |
| Apr 4, 2017 | Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer | |
| Apr 4, 2017 | Paul Sekhri joins Topas Therapeutics as Chairman of the Board | |
| Feb 27, 2017 | Arsanis and Adimab Enter Into License Agreement | |
| Jan 24, 2017 | Arsanis Announces First Patient Dosed in Global Phase 2 Study | |
| Jan 10, 2017 | Crescendo partners with Genedata | |
| Jan 9, 2017 | Luxendo announces Series A extension | |
| Dec 20, 2016 | Opsona announces preliminary MDS results | |
| Oct 25, 2016 | Opsona receives orphan designation | |
| Oct 10, 2016 | Crescendo enters a collaboration with Takeda | |
| Sep 28, 2016 | ViraT enters collaboration with Boehringer Ingelheim | |
| Sep 27, 2016 | Crescendo strengthens IP portfolio | |
| Mar 22, 2016 | Topas Series A Financing | |